GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (NAS:RDHL) » Definitions » Cyclically Adjusted PS Ratio

Redhill Biopharma (Redhill Biopharma) Cyclically Adjusted PS Ratio : 0.01 (As of May. 16, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Redhill Biopharma Cyclically Adjusted PS Ratio?

As of today (2024-05-16), Redhill Biopharma's current share price is $0.4723. Redhill Biopharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2023 was $32.08. Redhill Biopharma's Cyclically Adjusted PS Ratio for today is 0.01.

The historical rank and industry rank for Redhill Biopharma's Cyclically Adjusted PS Ratio or its related term are showing as below:

RDHL' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.7   Max: 18.76
Current: 0.01

During the past years, Redhill Biopharma's highest Cyclically Adjusted PS Ratio was 18.76. The lowest was 0.01. And the median was 0.70.

RDHL's Cyclically Adjusted PS Ratio is ranked better than
99.87% of 747 companies
in the Drug Manufacturers industry
Industry Median: 2.17 vs RDHL: 0.01

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Redhill Biopharma's adjusted revenue per share data for the three months ended in Jun. 2023 was $0.463. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $32.08 for the trailing ten years ended in Jun. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Redhill Biopharma Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Redhill Biopharma's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma Cyclically Adjusted PS Ratio Chart

Redhill Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 4.16 0.18 -

Redhill Biopharma Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.66 0.18 0.13 0.04 -

Competitive Comparison of Redhill Biopharma's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Redhill Biopharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Redhill Biopharma's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Redhill Biopharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Redhill Biopharma's Cyclically Adjusted PS Ratio falls into.



Redhill Biopharma Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Redhill Biopharma's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.4723/32.08
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Redhill Biopharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2023 is calculated as:

For example, Redhill Biopharma's adjusted Revenue per Share data for the three months ended in Jun. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=0.463/128.7287*128.7287
=0.463

Current CPI (Jun. 2023) = 128.7287.

Redhill Biopharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201309 0.019 98.790 0.025
201312 0.006 98.326 0.008
201403 30.859 99.695 39.846
201406 0.018 100.560 0.023
201409 0.018 100.428 0.023
201412 0.005 99.070 0.006
201503 0.004 99.621 0.005
201506 0.004 100.684 0.005
201509 0.003 100.392 0.004
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.003 101.688 0.004
201609 0.000 101.861 0.000
201612 0.302 101.863 0.382
201703 0.000 102.862 0.000
201706 1.126 103.349 1.403
201709 3.550 104.136 4.388
201712 4.143 104.011 5.128
201803 4.587 105.290 5.608
201806 4.401 106.317 5.329
201809 3.758 106.507 4.542
201812 2.065 105.998 2.508
201903 2.450 107.251 2.941
201906 2.205 108.070 2.627
201909 1.976 108.329 2.348
201912 1.888 108.420 2.242
202003 1.197 108.902 1.415
202006 23.377 108.767 27.667
202009 22.471 109.815 26.341
202012 22.662 109.897 26.545
202103 19.157 111.754 22.067
202106 18.425 114.631 20.691
202109 18.469 115.734 20.543
202112 17.799 117.630 19.478
202203 10.214 121.301 10.839
202206 12.911 125.017 13.294
202209 10.997 125.227 11.305
202212 6.990 125.222 7.186
202303 1.433 127.348 1.449
202306 0.463 128.729 0.463

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Redhill Biopharma  (NAS:RDHL) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Redhill Biopharma Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Redhill Biopharma (Redhill Biopharma) Business Description

Traded in Other Exchanges
Address
21 Ha’arba’a Street, Tel Aviv, ISR, 6473921
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.